Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

…, CY Liu, HJ Chen, JW Huang, IK Kim, CW Shiau

Index: Chen, Kuen-Feng; Pao, Kuan-Chuan; Su, Jung-Chen; Chou, Yi-Chieh; Liu, Chun-Yu; Chen, Hui-Ju; Huang, Jui-Wen; Kim, Inki; Shiau, Chung-Wai Bioorganic and Medicinal Chemistry, 2012 , vol. 20, # 20 p. 6144 - 6153

Full Text: HTML

Citation Number: 20

Abstract

Cancerous inhibitor of PP2A (CIP2A) is a novel human oncoprotein that inhibits PP2A, contributing to tumor aggressiveness in various cancers. Several studies have shown that downregulation of CIP2A by small molecules reduces PP2A-dependent phosphorylation of Akt and induces cell death. Here, a series of mono-and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were ...

Related Articles:

Design, synthesis and structure–activity relationship (SAR) studies of 2, 4-disubstituted pyrimidine derivatives: Dual activity as cholinesterase and Aβ-aggregation …

[Mohamed, Tarek; Zhao, Xiaobei; Habib, Lila K.; Yang, Jerry; Rao, Praveen P.N. Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 7 p. 2269 - 2281]

Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe …

[Coombs, Thomas C.; Tanega, Cordelle; Shen, Min; Wang, Jenna L.; Auld, Douglas S.; Gerritz, Samuel W.; Schoenen, Frank J.; Thomas, Craig J.; Aube, Jeffrey Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3654 - 3661]

More Articles...